{"transactions":[{"id":729963,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":30038,"kind":"organization","name":"Coastlands Capital LP","position":1,"cik":"0002068530","reported_name":"Coastlands Capital LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T14:30:53.000Z","date":"2026-06-17","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":0.53,"value":53000.0,"ownership":{"direct":false,"nature":"By Coastlands Capital LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Coastlands Capital LP (\"Coastlands\") and Coastlands Capital GP LLC (the \"General Partner\") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the \"Partnership\"). Coastlands Capital LLC (\"Coastlands GP\") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein."}],"balance_after":3835035,"source":{"system":"sec-edgar","filing":"0001104659-26-076184","document":"tm2618440-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841330/000110465926076184/tm2618440-1_4seq1.xml","form_type":"4"}},{"id":791919,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-05T20:42:20.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":1756069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the \"Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan)."}],"balance_after":1756069,"derivative":{"exercise_price":0.841,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":1756069},"source":{"system":"sec-edgar","filing":"0001213900-26-052262","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390026052262/ownership.xml","form_type":"4"}},{"id":792321,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-05T20:42:04.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":152783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the \"Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan)."}],"balance_after":152783,"derivative":{"exercise_price":0.841,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":152783},"source":{"system":"sec-edgar","filing":"0001213900-26-052261","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390026052261/ownership.xml","form_type":"4"}},{"id":791920,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49674,"kind":"person","name":"Dumesnil Simon","position":1,"cik":"0001875691","reported_name":"Dumesnil Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-05T20:41:48.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":152783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the \"Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan)."}],"balance_after":152783,"derivative":{"exercise_price":0.841,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":152783},"source":{"system":"sec-edgar","filing":"0001213900-26-052260","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875691/000121390026052260/ownership.xml","form_type":"4"}},{"id":791229,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49607,"kind":"person","name":"Schneiderman Daniel H","position":1,"cik":"0001565536","reported_name":"Schneiderman Daniel H","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-05T20:41:34.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":1129323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the \"Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan)."}],"balance_after":1129323,"derivative":{"exercise_price":0.841,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":1129323},"source":{"system":"sec-edgar","filing":"0001213900-26-052259","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1565536/000121390026052259/ownership.xml","form_type":"4"}},{"id":790993,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49594,"kind":"person","name":"Krishnan Kartik","position":1,"cik":"0002131061","reported_name":"Krishnan Kartik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-05T20:41:20.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":1129323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the \"Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan)."}],"balance_after":1129323,"derivative":{"exercise_price":0.841,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":1129323},"source":{"system":"sec-edgar","filing":"0001213900-26-052258","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390026052258/ownership.xml","form_type":"4"}},{"id":792831,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":29601,"kind":"person","name":"Leahy Emer","position":1,"cik":"0001875180","reported_name":"Leahy Emer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-05T20:41:05.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":152783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the \"Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan)."}],"balance_after":152783,"derivative":{"exercise_price":0.841,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":152783},"source":{"system":"sec-edgar","filing":"0001213900-26-052257","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875180/000121390026052257/ownership.xml","form_type":"4"}},{"id":791316,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49617,"kind":"person","name":"Novak Alfred J","position":1,"cik":"0001388862","reported_name":"Novak Alfred J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-05T20:40:50.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":152783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the \"Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan)."}],"balance_after":152783,"derivative":{"exercise_price":0.841,"expiration_date":"2036-04-30","underlying":"Common Stock","underlying_shares":152783},"source":{"system":"sec-edgar","filing":"0001213900-26-052256","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388862/000121390026052256/ownership.xml","form_type":"4"}},{"id":985368,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T14:07:14.000Z","date":"2025-11-28","kind":"purchase","planned":false,"acquired":true,"shares":133333,"price":0.75,"value":99999.75,"ownership":{"direct":true},"balance_after":199691,"source":{"system":"sec-edgar","filing":"0001213900-25-116309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390025116309/ownership.xml","form_type":"4"}},{"id":984841,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49607,"kind":"person","name":"Schneiderman Daniel H","position":1,"cik":"0001565536","reported_name":"Schneiderman Daniel H","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-01T14:04:30.000Z","date":"2025-11-28","kind":"grant","planned":false,"acquired":true,"shares":26667,"price":0.75,"value":20000.25,"ownership":{"direct":true},"balance_after":26667,"source":{"system":"sec-edgar","filing":"0001213900-25-116306","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1565536/000121390025116306/ownership.xml","form_type":"4"}},{"id":985224,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-01T13:56:56.000Z","date":"2025-11-28","kind":"purchase","planned":false,"acquired":true,"shares":33333,"price":0.75,"value":24999.75,"ownership":{"direct":true},"balance_after":73334,"source":{"system":"sec-edgar","filing":"0001213900-25-116301","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390025116301/ownership.xml","form_type":"4"}},{"id":985226,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49674,"kind":"person","name":"Dumesnil Simon","position":1,"cik":"0001875691","reported_name":"Dumesnil Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T13:54:08.000Z","date":"2025-11-28","kind":"purchase","planned":false,"acquired":true,"shares":33333,"price":0.75,"value":24999.75,"ownership":{"direct":true},"balance_after":35833,"source":{"system":"sec-edgar","filing":"0001213900-25-116299","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875691/000121390025116299/ownership.xml","form_type":"4"}},{"id":985704,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":29601,"kind":"person","name":"Leahy Emer","position":1,"cik":"0001875180","reported_name":"Leahy Emer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T13:51:18.000Z","date":"2025-11-28","kind":"grant","planned":false,"acquired":true,"shares":33333,"price":0.75,"value":24999.75,"ownership":{"direct":true},"balance_after":33333,"source":{"system":"sec-edgar","filing":"0001213900-25-116296","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875180/000121390025116296/ownership.xml","form_type":"4"}},{"id":1013346,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-10-27T21:27:18.000Z","date":"2025-10-24","kind":"grant","planned":false,"acquired":true,"shares":242913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the \"Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan)."}],"balance_after":242913,"derivative":{"exercise_price":0.715,"expiration_date":"2035-10-23","underlying":"Common Stock","underlying_shares":242913},"source":{"system":"sec-edgar","filing":"0001213900-25-102682","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390025102682/ownership.xml","form_type":"4"}},{"id":1013106,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49607,"kind":"person","name":"Schneiderman Daniel H","position":1,"cik":"0001565536","reported_name":"Schneiderman Daniel H","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-10-27T21:27:02.000Z","date":"2025-10-24","kind":"grant","planned":false,"acquired":true,"shares":317266,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the \"Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan)."}],"balance_after":317266,"derivative":{"exercise_price":0.715,"expiration_date":"2035-10-23","underlying":"Common Stock","underlying_shares":317266},"source":{"system":"sec-edgar","filing":"0001213900-25-102681","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1565536/000121390025102681/ownership.xml","form_type":"4"}},{"id":1013110,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49617,"kind":"person","name":"Novak Alfred J","position":1,"cik":"0001388862","reported_name":"Novak Alfred J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-10-27T21:26:45.000Z","date":"2025-10-24","kind":"grant","planned":false,"acquired":true,"shares":42913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the \"Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan)."}],"balance_after":42913,"derivative":{"exercise_price":0.715,"expiration_date":"2035-10-23","underlying":"Common Stock","underlying_shares":42913},"source":{"system":"sec-edgar","filing":"0001213900-25-102680","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388862/000121390025102680/ownership.xml","form_type":"4"}},{"id":1013283,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-10-27T21:26:30.000Z","date":"2025-10-24","kind":"grant","planned":false,"acquired":true,"shares":493341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the \"Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan)."}],"balance_after":493341,"derivative":{"exercise_price":0.715,"expiration_date":"2035-10-23","underlying":"Common Stock","underlying_shares":493341},"source":{"system":"sec-edgar","filing":"0001213900-25-102677","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390025102677/ownership.xml","form_type":"4"}},{"id":1013443,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":29601,"kind":"person","name":"Leahy Emer","position":1,"cik":"0001875180","reported_name":"Leahy Emer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-10-27T21:26:14.000Z","date":"2025-10-24","kind":"grant","planned":false,"acquired":true,"shares":42913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the \"Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan)."}],"balance_after":42913,"derivative":{"exercise_price":0.715,"expiration_date":"2035-10-23","underlying":"Common Stock","underlying_shares":42913},"source":{"system":"sec-edgar","filing":"0001213900-25-102676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875180/000121390025102676/ownership.xml","form_type":"4"}},{"id":1013284,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49674,"kind":"person","name":"Dumesnil Simon","position":1,"cik":"0001875691","reported_name":"Dumesnil Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-10-27T21:25:59.000Z","date":"2025-10-24","kind":"grant","planned":false,"acquired":true,"shares":42913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the \"Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan)."}],"balance_after":42913,"derivative":{"exercise_price":0.715,"expiration_date":"2035-10-23","underlying":"Common Stock","underlying_shares":42913},"source":{"system":"sec-edgar","filing":"0001213900-25-102674","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875691/000121390025102674/ownership.xml","form_type":"4"}},{"id":1149367,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-05-15T01:55:17.000Z","date":"2025-05-12","kind":"sale","planned":false,"acquired":false,"shares":960,"price":0.825,"value":792.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person previously held 960 shares of Common Stock of the Issuer in a foreign brokerage account that was recently wound down. As a result, the foreign broker automatically liquidated the Reportion Person's account on May 12, 2025 by selling the 960 shares of Common Stock of the Issuer on a non-discretionary basis."}],"balance_after":40001,"source":{"system":"sec-edgar","filing":"0001213900-25-043621","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390025043621/ownership.xml","form_type":"4"}},{"id":1478629,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49617,"kind":"person","name":"Novak Alfred J","position":1,"cik":"0001388862","reported_name":"Novak Alfred J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-14T21:25:21.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":2750,"price":5.62,"value":15455.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.55 to $5.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":3500,"source":{"system":"sec-edgar","filing":"0001213900-24-053005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388862/000121390024053005/ownership.xml","form_type":"4"}},{"id":1478628,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49617,"kind":"person","name":"Novak Alfred J","position":1,"cik":"0001388862","reported_name":"Novak Alfred J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-14T21:25:21.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":750,"price":5.61,"value":4207.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.60 to $5.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (\"SEC\"), upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":750,"source":{"system":"sec-edgar","filing":"0001213900-24-053005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388862/000121390024053005/ownership.xml","form_type":"4"}},{"id":1546901,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-06T01:45:31.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":11669,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on March 1, 2024, was $8.13 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option award was made in accordance with the terms of the 2023 Plan. The option award fully vested upon issuance and became exercisable on March 1, 2024."}],"balance_after":11669,"derivative":{"exercise_price":8.13,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":11669},"source":{"system":"sec-edgar","filing":"0001213900-24-030963","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390024030963/ownership.xml","form_type":"4/A","original_submission_date":"2024-03-01"}},{"id":1546900,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-06T01:45:31.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on March 1, 2024, was $8.13 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan (the \"2023 Plan\"). The shares of Common Stock underlying the option award will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains a director or otherwise in continuous service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":8.13,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001213900-24-030963","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390024030963/ownership.xml","form_type":"4/A","original_submission_date":"2024-03-01"}},{"id":1546902,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49674,"kind":"person","name":"Dumesnil Simon","position":1,"cik":"0001875691","reported_name":"Dumesnil Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-06T01:45:30.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on March 1, 2024, was $8.13 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of Common Stock underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":8.13,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-030958","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875691/000121390024030958/ownership.xml","form_type":"4/A","original_submission_date":"2024-03-01"}},{"id":1546452,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49607,"kind":"person","name":"Schneiderman Daniel H","position":1,"cik":"0001565536","reported_name":"Schneiderman Daniel H","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-06T01:45:26.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":5927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on March 1, 2024, was $8.13 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option award was made in accordance with the terms of the 2023 Plan. The option award fully vested upon issuance and became exercisable on March 1, 2024."}],"balance_after":5927,"derivative":{"exercise_price":8.13,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":5927},"source":{"system":"sec-edgar","filing":"0001213900-24-030961","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1565536/000121390024030961/ownership.xml","form_type":"4/A","original_submission_date":"2024-03-01"}},{"id":1546451,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49607,"kind":"person","name":"Schneiderman Daniel H","position":1,"cik":"0001565536","reported_name":"Schneiderman Daniel H","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-06T01:45:26.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on March 1, 2024, was $8.13 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan (the \"2023 Plan\"). The shares of Common Stock underlying the option award will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":8.13,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001213900-24-030961","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1565536/000121390024030961/ownership.xml","form_type":"4/A","original_submission_date":"2024-03-01"}},{"id":1547264,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":29601,"kind":"person","name":"Leahy Emer","position":1,"cik":"0001875180","reported_name":"Leahy Emer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-06T01:45:21.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on March 1, 2024, was $8.13 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award (the \"Option\") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of Common Stock underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":8.13,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-030962","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875180/000121390024030962/ownership.xml","form_type":"4/A","original_submission_date":"2024-03-01"}},{"id":1546505,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49617,"kind":"person","name":"Novak Alfred J","position":1,"cik":"0001388862","reported_name":"Novak Alfred J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-06T01:45:18.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on March 1, 2024, was $8.13 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award (the \"Option\") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of Common Stock underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date."}],"balance_after":5000,"derivative":{"exercise_price":8.13,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001213900-24-030960","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388862/000121390024030960/ownership.xml","form_type":"4/A","original_submission_date":"2024-03-01"}},{"id":1546322,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":92175,"kind":"person","name":"Currie Graeme Martin","position":1,"cik":"0001965006","reported_name":"Currie Graeme Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-06T01:45:13.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":5938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on March 1, 2024, was $8.13 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award (the \"Option\") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The Option fully vested upon issuance and became exercisable on March 1, 2024."}],"balance_after":5938,"derivative":{"exercise_price":8.13,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":5938},"source":{"system":"sec-edgar","filing":"0001213900-24-030959","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390024030959/ownership.xml","form_type":"4/A","original_submission_date":"2024-03-01"}},{"id":1547030,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-06T01:45:10.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on March 1, 2024, was $8.13 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award (the \"Option\") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of Common Stock underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":8.13,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-030957","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390024030957/ownership.xml","form_type":"4/A","original_submission_date":"2024-03-01"}},{"id":1607772,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-02T02:47:15.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award (the \"Option\") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":8.34,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-019222","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390024019222/ownership.xml","form_type":"4"}},{"id":1606236,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49607,"kind":"person","name":"Schneiderman Daniel H","position":1,"cik":"0001565536","reported_name":"Schneiderman Daniel H","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-02T02:46:57.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":5927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award was made in accordance with the terms of the 2023 Plan. The option award fully vested upon issuance and became exercisable on March 1, 2024."}],"balance_after":5927,"derivative":{"exercise_price":8.34,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":5927},"source":{"system":"sec-edgar","filing":"0001213900-24-019221","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1565536/000121390024019221/ownership.xml","form_type":"4"}},{"id":1606235,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49607,"kind":"person","name":"Schneiderman Daniel H","position":1,"cik":"0001565536","reported_name":"Schneiderman Daniel H","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-02T02:46:57.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan (the \"2023 Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), underlying the option award will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":8.34,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001213900-24-019221","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1565536/000121390024019221/ownership.xml","form_type":"4"}},{"id":1606454,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49617,"kind":"person","name":"Novak Alfred J","position":1,"cik":"0001388862","reported_name":"Novak Alfred J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-02T02:46:39.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award (the \"Option\") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date."}],"balance_after":5000,"derivative":{"exercise_price":8.34,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001213900-24-019220","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388862/000121390024019220/ownership.xml","form_type":"4"}},{"id":1607547,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-02T02:46:21.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":11669,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award was made in accordance with the terms of the 2023 Plan. The option award fully vested upon issuance and became exercisable on March 1, 2024."}],"balance_after":11669,"derivative":{"exercise_price":8.34,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":11669},"source":{"system":"sec-edgar","filing":"0001213900-24-019219","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390024019219/ownership.xml","form_type":"4"}},{"id":1607546,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-02T02:46:21.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan (the \"2023 Plan\"). The shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), underlying the option award will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains a director or otherwise in continuous service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":8.34,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001213900-24-019219","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390024019219/ownership.xml","form_type":"4"}},{"id":1608624,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":29601,"kind":"person","name":"Leahy Emer","position":1,"cik":"0001875180","reported_name":"Leahy Emer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-02T02:46:04.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award (the \"Option\") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":8.34,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-019218","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875180/000121390024019218/ownership.xml","form_type":"4"}},{"id":1607549,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49674,"kind":"person","name":"Dumesnil Simon","position":1,"cik":"0001875691","reported_name":"Dumesnil Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-02T02:45:45.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option (the \"Option\") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":8.34,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-019217","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875691/000121390024019217/ownership.xml","form_type":"4"}},{"id":1605745,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":92175,"kind":"person","name":"Currie Graeme Martin","position":1,"cik":"0001965006","reported_name":"Currie Graeme Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-02T02:45:23.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":5938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award (the \"Option\") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The Option fully vested upon issuance and became exercisable on March 1, 2024."}],"balance_after":5938,"derivative":{"exercise_price":8.34,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":5938},"source":{"system":"sec-edgar","filing":"0001213900-24-019216","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390024019216/ownership.xml","form_type":"4"}},{"id":1865500,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-07T01:00:08.000Z","date":"2023-06-02","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":0.431,"value":12930.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.38 to $0.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":1327174,"source":{"system":"sec-edgar","filing":"0001493152-23-020333","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000149315223020333/ownership.xml","form_type":"4"}},{"id":2103557,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-28T21:00:26.000Z","date":"2022-11-28","kind":"grant","acquired":true,"shares":5000,"price":0.98,"value":4900.0,"ownership":{"direct":true},"balance_after":1287174,"source":{"system":"sec-edgar","filing":"0001213900-22-075491","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390022075491/ownership.xml","form_type":"4"}},{"id":2103502,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-28T21:00:14.000Z","date":"2022-11-25","kind":"grant","acquired":true,"shares":2000,"price":1.03,"value":2060.0,"ownership":{"direct":true},"balance_after":819206,"source":{"system":"sec-edgar","filing":"0001213900-22-075490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022075490/ownership.xml","form_type":"4"}},{"id":2103501,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-28T21:00:14.000Z","date":"2022-11-23","kind":"grant","acquired":true,"shares":1206,"price":1.02,"value":1230.12,"ownership":{"direct":true},"balance_after":817206,"source":{"system":"sec-edgar","filing":"0001213900-22-075490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022075490/ownership.xml","form_type":"4"}},{"id":2103500,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-28T21:00:14.000Z","date":"2022-11-23","kind":"grant","acquired":true,"shares":1000,"price":1.03,"value":1030.0,"ownership":{"direct":true},"balance_after":816000,"source":{"system":"sec-edgar","filing":"0001213900-22-075490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022075490/ownership.xml","form_type":"4"}},{"id":2103499,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-11-28T21:00:14.000Z","date":"2022-11-23","kind":"grant","acquired":true,"shares":5000,"price":1,"value":5000.0,"ownership":{"direct":true},"balance_after":815000,"source":{"system":"sec-edgar","filing":"0001213900-22-075490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022075490/ownership.xml","form_type":"4"}},{"id":2107289,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-22T21:10:19.000Z","date":"2022-11-22","kind":"grant","acquired":true,"shares":5000,"price":0.99,"value":4950.0,"ownership":{"direct":true},"balance_after":1282174,"source":{"system":"sec-edgar","filing":"0001213900-22-074585","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390022074585/ownership.xml","form_type":"4"}},{"id":2112577,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49674,"kind":"person","name":"Dumesnil Simon","position":1,"cik":"0001875691","reported_name":"Dumesnil Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (to acquire Common Stock)","published_at":"2022-11-17T21:34:41.000Z","date":"2021-08-02","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person was granted 100,000 stock options which have a ten-year term. The option is vested and exercisable with regard to 50,000 shares of Common Stock. The remaining 50% vest, subject to Mr. Dumesnil's remaining employed and in good standing, on August 2, 2023."}],"balance_after":100000,"derivative":{"exercise_price":6,"exercise_date":"2022-08-02","expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-22-073502","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1875691/000121390022073502/ownership.xml","form_type":"4"}},{"id":2112576,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49674,"kind":"person","name":"Dumesnil Simon","position":1,"cik":"0001875691","reported_name":"Dumesnil Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-17T21:34:41.000Z","date":"2022-11-17","kind":"grant","acquired":true,"shares":40000,"price":1.06,"value":42400.0,"ownership":{"direct":true},"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001213900-22-073502","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875691/000121390022073502/ownership.xml","form_type":"4"}},{"id":2112575,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49674,"kind":"person","name":"Dumesnil Simon","position":1,"cik":"0001875691","reported_name":"Dumesnil Simon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-17T21:34:41.000Z","date":"2022-11-15","kind":"grant","acquired":true,"shares":10000,"price":1.07,"value":10700.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001213900-22-073502","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875691/000121390022073502/ownership.xml","form_type":"4"}},{"id":2131811,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-26T21:35:52.000Z","date":"2022-10-26","kind":"grant","acquired":true,"shares":5000,"price":1.1,"value":5500.0,"ownership":{"direct":true},"balance_after":1277174,"source":{"system":"sec-edgar","filing":"0001213900-22-066554","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390022066554/ownership.xml","form_type":"4"}},{"id":2132819,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49617,"kind":"person","name":"Novak Alfred J","position":1,"cik":"0001388862","reported_name":"Novak Alfred J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (to acquire Common Stock)","published_at":"2022-10-24T14:15:40.000Z","date":"2022-10-21","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person was granted 100,000 stock options. The stock options have a ten-year term and vest over two years, subject to Mr. Novak's continued service as a director, one-half vesting on the first anniversary of the grant date, and the remaining 50% vesting on the second anniversary of the grant date."}],"balance_after":100000,"derivative":{"exercise_price":1.06,"exercise_date":"2023-10-21","expiration_date":"2032-10-21","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-22-065696","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388862/000121390022065696/ownership.xml","form_type":"4"}},{"id":2133655,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-21T21:05:27.000Z","date":"2022-10-21","kind":"grant","acquired":true,"shares":4400,"price":1.07,"value":4708.0,"ownership":{"direct":true},"balance_after":810000,"source":{"system":"sec-edgar","filing":"0001213900-22-065571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022065571/ownership.xml","form_type":"4"}},{"id":2133654,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-10-21T21:05:27.000Z","date":"2022-10-21","kind":"grant","acquired":true,"shares":600,"price":1.08,"value":648.0,"ownership":{"direct":true},"balance_after":805600,"source":{"system":"sec-edgar","filing":"0001213900-22-065571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022065571/ownership.xml","form_type":"4"}},{"id":2134374,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":122998,"kind":"person","name":"Delaney David","position":1,"cik":"0001943013","reported_name":"Delaney David","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":122999,"kind":"organization","name":"Concord IP2 Ltd.","position":2,"cik":"0001943018","reported_name":"Concord IP2 Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":123000,"kind":"organization","name":"Elderhill Corp","position":3,"cik":"0001943046","reported_name":"Elderhill Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Common Stock","published_at":"2022-10-19T21:29:22.000Z","date":"2022-10-17","kind":"purchase","acquired":true,"shares":1000,"price":1.11,"value":1110.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were purchased by Elderhill Corporation, of which David Delaney serves as sole director and President."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"191,321 shares are held by Concord IP2, Ltd., of which David Delaney serves as sole director and President, and 36,200 shares are held by Elderhill Corporation."}],"balance_after":227521,"source":{"system":"sec-edgar","filing":"0001209191-22-054100","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841330/000120919122054100/doc4.xml","form_type":"4"}},{"id":2136460,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-17T22:11:13.000Z","date":"2022-10-17","kind":"grant","acquired":true,"shares":9000,"price":1.13,"value":10170.0,"ownership":{"direct":true},"balance_after":1272174,"source":{"system":"sec-edgar","filing":"0001213900-22-064401","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390022064401/ownership.xml","form_type":"4"}},{"id":2136459,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-17T22:11:13.000Z","date":"2022-10-17","kind":"grant","acquired":true,"shares":1000,"price":1.14,"value":1140.0,"ownership":{"direct":true},"balance_after":1263174,"source":{"system":"sec-edgar","filing":"0001213900-22-064401","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390022064401/ownership.xml","form_type":"4"}},{"id":2138126,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49607,"kind":"person","name":"Schneiderman Daniel H","position":1,"cik":"0001565536","reported_name":"Schneiderman Daniel H","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (to acquire Common Stock)","published_at":"2022-10-13T00:15:34.000Z","date":"2022-10-11","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person was granted 300,000 stock options. The stock options have a ten-year term and vest over three years, subject to Mr. Schneiderman remaining employed and in good standing, one-third vesting 12 months after the grant date, and the remainder vesting in equal tranches monthly for two years thereinafter."}],"balance_after":300000,"derivative":{"exercise_price":1.26,"exercise_date":"2023-10-11","expiration_date":"2032-10-11","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001213900-22-063616","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1565536/000121390022063616/ownership.xml","form_type":"4"}},{"id":2148611,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":29312,"kind":"person","name":"Shahinian Eric","position":1,"cik":"0001790877","reported_name":"Shahinian Eric","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29311,"kind":"organization","name":"Camac Capital, LLC","position":2,"cik":"0001867498","reported_name":"Camac Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29309,"kind":"organization","name":"Camac Fund, LP","position":3,"cik":"0001516478","reported_name":"Camac Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29310,"kind":"organization","name":"Camac Partners, LLC","position":4,"cik":"0001867496","reported_name":"Camac Partners, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Common Stock","published_at":"2022-09-30T20:36:00.000Z","date":"2022-09-29","kind":"purchase","acquired":true,"shares":6710,"price":1.156,"value":7756.76,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Camac Fund, LP. (\"Camac Fund\"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC."}],"balance_after":1788415,"source":{"system":"sec-edgar","filing":"0001209191-22-051650","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516478/000120919122051650/doc4.xml","form_type":"4"}},{"id":2148610,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":29312,"kind":"person","name":"Shahinian Eric","position":1,"cik":"0001790877","reported_name":"Shahinian Eric","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29311,"kind":"organization","name":"Camac Capital, LLC","position":2,"cik":"0001867498","reported_name":"Camac Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29309,"kind":"organization","name":"Camac Fund, LP","position":3,"cik":"0001516478","reported_name":"Camac Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29310,"kind":"organization","name":"Camac Partners, LLC","position":4,"cik":"0001867496","reported_name":"Camac Partners, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Common Stock","published_at":"2022-09-30T20:36:00.000Z","date":"2022-09-28","kind":"purchase","acquired":true,"shares":57647,"price":1.189,"value":68542.283,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Camac Fund, LP. (\"Camac Fund\"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC."}],"balance_after":1781705,"source":{"system":"sec-edgar","filing":"0001209191-22-051650","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516478/000120919122051650/doc4.xml","form_type":"4"}},{"id":2165127,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":29312,"kind":"person","name":"Shahinian Eric","position":1,"cik":"0001790877","reported_name":"Shahinian Eric","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29311,"kind":"organization","name":"Camac Capital, LLC","position":2,"cik":"0001867498","reported_name":"Camac Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29309,"kind":"organization","name":"Camac Fund, LP","position":3,"cik":"0001516478","reported_name":"Camac Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29310,"kind":"organization","name":"Camac Partners, LLC","position":4,"cik":"0001867496","reported_name":"Camac Partners, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Common Stock","published_at":"2022-09-06T21:03:49.000Z","date":"2022-09-06","kind":"purchase","acquired":true,"shares":21748,"price":1.1326,"value":24631.7848,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Camac Fund, LP. (\"Camac Fund\"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC."}],"balance_after":1724058,"source":{"system":"sec-edgar","filing":"0001209191-22-048789","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1516478/000120919122048789/doc4.xml","form_type":"4"}},{"id":2165126,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":29312,"kind":"person","name":"Shahinian Eric","position":1,"cik":"0001790877","reported_name":"Shahinian Eric","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29311,"kind":"organization","name":"Camac Capital, LLC","position":2,"cik":"0001867498","reported_name":"Camac Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29309,"kind":"organization","name":"Camac Fund, LP","position":3,"cik":"0001516478","reported_name":"Camac Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29310,"kind":"organization","name":"Camac Partners, LLC","position":4,"cik":"0001867496","reported_name":"Camac Partners, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Common Stock","published_at":"2022-09-06T21:03:49.000Z","date":"2022-09-02","kind":"purchase","acquired":true,"shares":11507,"price":1.1389,"value":13105.3223,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Camac Fund, LP. (\"Camac Fund\"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC."}],"balance_after":1702310,"source":{"system":"sec-edgar","filing":"0001209191-22-048789","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516478/000120919122048789/doc4.xml","form_type":"4"}},{"id":2165125,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":29312,"kind":"person","name":"Shahinian Eric","position":1,"cik":"0001790877","reported_name":"Shahinian Eric","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29311,"kind":"organization","name":"Camac Capital, LLC","position":2,"cik":"0001867498","reported_name":"Camac Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29309,"kind":"organization","name":"Camac Fund, LP","position":3,"cik":"0001516478","reported_name":"Camac Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29310,"kind":"organization","name":"Camac Partners, LLC","position":4,"cik":"0001867496","reported_name":"Camac Partners, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Common Stock","published_at":"2022-09-06T21:03:49.000Z","date":"2022-09-01","kind":"purchase","acquired":true,"shares":55646,"price":1.1255,"value":62629.573,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Camac Fund, LP. (\"Camac Fund\"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC."}],"balance_after":1690803,"source":{"system":"sec-edgar","filing":"0001209191-22-048789","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516478/000120919122048789/doc4.xml","form_type":"4"}},{"id":2169819,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":29312,"kind":"person","name":"Shahinian Eric","position":1,"cik":"0001790877","reported_name":"Shahinian Eric","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29311,"kind":"organization","name":"Camac Capital, LLC","position":2,"cik":"0001867498","reported_name":"Camac Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29309,"kind":"organization","name":"Camac Fund, LP","position":3,"cik":"0001516478","reported_name":"Camac Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29310,"kind":"organization","name":"Camac Partners, LLC","position":4,"cik":"0001867496","reported_name":"Camac Partners, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Common Stock","published_at":"2022-08-31T20:32:16.000Z","date":"2022-08-30","kind":"purchase","acquired":true,"shares":17828,"price":1.1472,"value":20452.2816,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Camac Fund, LP. (\"Camac Fund\"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC."}],"balance_after":1635157,"source":{"system":"sec-edgar","filing":"0001209191-22-048135","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516478/000120919122048135/doc4.xml","form_type":"4"}},{"id":2169818,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":29312,"kind":"person","name":"Shahinian Eric","position":1,"cik":"0001790877","reported_name":"Shahinian Eric","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29311,"kind":"organization","name":"Camac Capital, LLC","position":2,"cik":"0001867498","reported_name":"Camac Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29309,"kind":"organization","name":"Camac Fund, LP","position":3,"cik":"0001516478","reported_name":"Camac Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29310,"kind":"organization","name":"Camac Partners, LLC","position":4,"cik":"0001867496","reported_name":"Camac Partners, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Common Stock","published_at":"2022-08-31T20:32:16.000Z","date":"2022-08-29","kind":"purchase","acquired":true,"shares":5000,"price":1.1681,"value":5840.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of shares beneficially owned includes 1,000 shares inadvertently omitted from the Reporting Persons' Form 3 filed 08/15/2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by Camac Fund, LP. (\"Camac Fund\"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC."}],"balance_after":1617329,"source":{"system":"sec-edgar","filing":"0001209191-22-048135","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516478/000120919122048135/doc4.xml","form_type":"4"}},{"id":2173031,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":35198,"kind":"person","name":"Geller Avi","position":1,"cik":"0001883076","reported_name":"Geller Avi","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":124214,"kind":"organization","name":"Leonite Fund I, LP","position":2,"cik":"0001944053","reported_name":"Leonite Fund I, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":124234,"kind":"organization","name":"Leonite Capital LLC","position":3,"cik":"0001824520","reported_name":"Leonite Capital LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}}],"security":"Common Stock","published_at":"2022-08-26T20:30:45.000Z","date":"2022-08-19","kind":"purchase","acquired":true,"shares":54644,"price":1.2982,"value":70938.8408,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Leonite Fund I, LP. Avi Geller is the Managing Member of Leonite Advisors LLC, which is the General Partner of Leonite Fund I, LP."}],"balance_after":54644,"source":{"system":"sec-edgar","filing":"0001209191-22-047714","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1883076/000120919122047714/doc4.xml","form_type":"4"}},{"id":2179162,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":29312,"kind":"person","name":"Shahinian Eric","position":1,"cik":"0001790877","reported_name":"Shahinian Eric","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group"}},{"id":29311,"kind":"organization","name":"Camac Capital, LLC","position":2,"cik":"0001867498","reported_name":"Camac Capital, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group."}},{"id":29309,"kind":"organization","name":"Camac Fund, LP","position":3,"cik":"0001516478","reported_name":"Camac Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group."}},{"id":29310,"kind":"organization","name":"Camac Partners, LLC","position":4,"cik":"0001867496","reported_name":"Camac Partners, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Member of 10% owner group."}}],"security":"Common Stock","published_at":"2022-08-18T23:35:09.000Z","date":"2022-08-17","kind":"purchase","acquired":true,"shares":155773,"price":1.2087,"value":188282.8251,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held by Camac Fund, LP. (\"Camac Fund\"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC."}],"balance_after":1611329,"source":{"system":"sec-edgar","filing":"0001493152-22-023502","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516478/000149315222023502/ownership.xml","form_type":"4"}},{"id":2218818,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-30T20:15:56.000Z","date":"2022-06-29","kind":"grant","acquired":true,"shares":5000,"price":1,"value":5000.0,"ownership":{"direct":true},"balance_after":1272174,"source":{"system":"sec-edgar","filing":"0001213900-22-036296","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390022036296/ownership.xml","form_type":"4"}},{"id":2218817,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-30T20:15:56.000Z","date":"2022-06-28","kind":"grant","acquired":true,"shares":5000,"price":1.02,"value":5100.0,"ownership":{"direct":true},"balance_after":1267174,"source":{"system":"sec-edgar","filing":"0001213900-22-036296","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390022036296/ownership.xml","form_type":"4"}},{"id":2221413,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-27T20:15:11.000Z","date":"2022-06-27","kind":"grant","acquired":true,"shares":5000,"price":1,"value":5000.0,"ownership":{"direct":true},"balance_after":1262174,"source":{"system":"sec-edgar","filing":"0001213900-22-035201","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390022035201/ownership.xml","form_type":"4"}},{"id":2223185,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-23T21:10:43.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":1800,"price":0.994,"value":1789.2,"ownership":{"direct":true},"balance_after":805000,"source":{"system":"sec-edgar","filing":"0001213900-22-034643","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022034643/ownership.xml","form_type":"4"}},{"id":2223184,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-23T21:10:43.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":100,"price":0.988,"value":98.8,"ownership":{"direct":true},"balance_after":803200,"source":{"system":"sec-edgar","filing":"0001213900-22-034643","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022034643/ownership.xml","form_type":"4"}},{"id":2223183,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-23T21:10:43.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":200,"price":0.982,"value":196.4,"ownership":{"direct":true},"balance_after":803100,"source":{"system":"sec-edgar","filing":"0001213900-22-034643","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022034643/ownership.xml","form_type":"4"}},{"id":2223182,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-23T21:10:43.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":2900,"price":0.993,"value":2879.7,"ownership":{"direct":true},"balance_after":802900,"source":{"system":"sec-edgar","filing":"0001213900-22-034643","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390022034643/ownership.xml","form_type":"4"}},{"id":2223199,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-23T20:31:12.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":5000,"price":1,"value":5000.0,"ownership":{"direct":true},"balance_after":1257174,"source":{"system":"sec-edgar","filing":"0001213900-22-034621","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390022034621/ownership.xml","form_type":"4"}},{"id":2224430,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (to acquire common stock)","published_at":"2022-06-22T20:30:46.000Z","date":"2021-08-02","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person was granted 100,000 stock options. The stock options have a ten-year term and vest over two years, subject to reporting person remaining employed and in good standing, one-half vesting on the first anniversary of the grant date, and the remainder vesting on the second anniversary of the grant date."}],"balance_after":100000,"derivative":{"exercise_price":6,"exercise_date":"2022-08-02","expiration_date":"2031-08-02","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001213900-22-034366","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390022034366/ownership.xml","form_type":"4"}},{"id":2224429,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49724,"kind":"person","name":"STEINMAN LAWRENCE","position":1,"cik":"0001132679","reported_name":"STEINMAN LAWRENCE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-22T20:30:46.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":652174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock of the Issuer issued in connection with the acquisition of the ALPHA-5 Integrin, LLC on June 21, 2022."}],"balance_after":1252174,"source":{"system":"sec-edgar","filing":"0001213900-22-034366","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1132679/000121390022034366/ownership.xml","form_type":"4"}},{"id":2461340,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (to acquire Common Stock)","published_at":"2021-12-22T22:00:09.000Z","date":"2021-12-20","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Reporting Person was granted 200,000 stock options. The stock options have a ten-year term and vest over three years, subject to Dr. Marques remaining employed and in good standing, one-third vesting 12 months after the grant date, and the remainder vesting in equal tranches quarterly for two years thereinafter."}],"balance_after":200000,"derivative":{"exercise_price":1.44,"exercise_date":"2022-12-20","expiration_date":"2031-12-20","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001213900-21-067062","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390021067062/ownership.xml","form_type":"4"}},{"id":2461339,"issuer":{"id":7685,"kind":"organization","name":"Pasithea Therapeutics Corp."},"owners":[{"id":49673,"kind":"person","name":"Marques Tiago","position":1,"cik":"0001875240","reported_name":"Marques Tiago","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-22T22:00:09.000Z","date":"2021-12-20","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person was granted Restricted Stock Units which shall vest into common stock of the Company over three years, subject to Dr. Marques remaining employed and in good standing, one-third vesting 12 months after the grant date, and the remainder vesting in equal tranches quarterly for two years thereinafter."}],"balance_after":800000,"source":{"system":"sec-edgar","filing":"0001213900-21-067062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875240/000121390021067062/ownership.xml","form_type":"4"}}]}